Larvol Delta - CERo-Therapeutics-Holdings-Inc-Announces-Sarah-Cannon-Research-Institute-at-Colorado-Blood-Cancer-Institute-as-Key-Clinical-Trial-Site-for-its-Phase-1-Clinical-Trial-of-CER1236-in-Acute-Myeloid-Leukemia

CER-1236 - CERo Therap

https://www.globenewswire.com/news-release/2025/04/24/3067391/0/en/CERo-Therapeutics-Holdings-Inc-Announces-Sarah-Cannon-Research-Institute-at-Colorado-Blood-Cancer-Institute-as-Key-Clinical-Trial-Site-for-its-Phase-1-Clinical-Trial-of-CER-1236-in.html

Apr 24, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next